New PLENVUR (NER1006) Data at ACG Showing Superior Bowel Cleansing to Commonly Used Preparations

– Norgine B.V. today presented new data demonstrating the superior high-quality bowel cleansing efficacy (in at least one segment of the colon) of PLENVUR (NER1006) compared to two widely used alternative bowel preparations: sodium picosulfate and magnesium salt solution (CITRAFLEETR) and 2-litre PEG with ascorbate (MOVIPREPR). The data were presented at the World Congress of Gastroenterology at the American College of Gastroenterology (ACG) in Orlando, Florida, USA. PLENVUR is a novel 1-litre polyethylene glycol (PEG)-based bowel preparation currently under regulatory review in the US and EU.

(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )

The post-hoc analysis of three phase III clinical trials – DAYB, MORA and NOCT – evaluated high-quality cleansing results (one segment with Boston Bowel Preparation Scale score 3 and all other segments scores >2). The results showed that PLENVUR produced significantly higher rates of high quality cleansing:

PLENVUR achieved similar high-quality cleansing results as a trisulfate solution in the NOCT study (32.6% vs. 35.1%, p=0.63). Assessment of adequate cleansing (BBPS segmental score >2) in the overall colon and the right colon showed that PLENVUR produced numerically higher results compared to all three alternative preparations.

A separate post-hoc analysis of the DAYB, MORA and NOCT trials found a positive relationship between cleansing grade and improved lesion detection rates, suggesting that high-quality bowel cleansing may improve polyp and adenoma detection rates in the overall colon.

Dr Cesare Hassan of the Nuovo Regina Margherita Hospital, Rome, Italy said, “These results confirm that PLENVUR achieves consistent excellent bowel cleansing, with lower volume intake, compared to widely used alternative preparations. Combined with the finding that better cleansing may improve polyp and adenoma detection, PLENVUR has the potential to improve outcomes and save healthcare resources.”

He added, “The very high quality of the PLENVUR studies emphasise that these results are robust and irreversible.”

Media Contacts:

Isabelle Jouin, T: +44(0)1895-453643Charlotte Andrews, T: +44(0)1895-453607

Follow us @norgine

(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)